The protein toxin Pasteurella multocida toxin (PMT) is the causative agent of atrophic rhinitis in pigs, leading to atrophy of the nasal turbinate bones by affecting osteoblasts and osteoclasts. The mechanism of PMT-induced intoxication is a deamidation of ␣-subunits of heterotrimeric G proteins, including G␣ q , G␣ 13 , and G␣ i , thereby causing persistent activation of the G proteins. Here we utilized PMT as a transporter of the non-cell-permeating A domain of diphtheria toxin (DTa). Fusion proteins of PMT and DTa ADP-ribosylated elongation factor 2, the natural target of diphtheria toxin, leading to cell toxicity. PMT-DTa effects were competed by PMT, indicating binding to the same cell surface receptor. Fluorescently labeled PMT-DTa and PMT colocalized with specific markers of early and late endosomes. Bafilomycin A, which inhibits vacuolar H ؉ -ATPase, blocked PMT-DTainduced intoxication of HEK-293 cells. By constructing various PMT-DTa chimeras, we identified a minimal region of PMT necessary for uptake of DTa. The data suggest that PMT is able to transport cargo proteins into eukaryotic cells by utilizing the PMT-specific uptake route.
P
asteurella multocida is a frequent commensal of the respiratory tract of animals. As a facultative pathogen, it can lead to severe and economically important diseases, such as shipping fever in cattle, snuffles in rabbits, and fowl cholera in poultry (1) . Zoonotic diseases normally arise from scratches, bites, and saliva from pet animals such as cats and dogs (2, 3) . One of the major virulence factors of P. multocida is the protein toxin PMT (P. multocida toxin), which is produced by serogroup D and some A strains (4) . PMT is the causative agent to induce atrophic rhinitis in pigs. This disease is characterized by shortening and twisting of the snout due to the loss of nasal turbinate bones (5, 6) .
PMT activates various heterotrimeric G proteins (7, 8) . Recently, we identified the molecular mechanism of the toxin as a deamidation of the ␣-subunits of heterotrimeric G proteins (9) . An essential glutamine residue in the switch II region of the GTPase domain of ␣-subunits is deamidated, resulting in a glutamic acid. Because the targeted glutamine is crucial for GTP hydrolysis by G proteins (10) , PMT-deamidated G proteins are constitutively activated. Many heterotrimeric G proteins are substrates of the toxin. PMT activates the G␣ q/11 family to induce phospholipase C␤ stimulation and, subsequently, stimulates Ca 2ϩ and protein kinase C signaling (11, 12) . Also, G␣ 12/13 proteins, which trigger RhoA activation via RhoGEF proteins, are targets of the toxin (13, 14) . Moreover, PMT activates G␣ i1-3 , leading to inhibition of the adenylyl cyclase (15) . However, the fourth family of heterotrimeric G proteins, G␣ s , is not a substrate of PMT. Besides activating ␣-subunits of G proteins, the toxin induces the release of G␤␥, thereby stimulating G␤␥-dependent signaling. For example, phosphoinositide-3-kinase ␥ is stimulated by this signaling pathway (16) . PMT-induced activation of G proteins leads to strong mitogenic and antiapoptotic effects and affects cell differentiation processes (17) (18) (19) . Notably, the identical glutamine residue of G␣ q/11 , which is targeted by PMT, was identified as a mutation site in melanoma and blue nevi (20) .
The 146-kDa toxin PMT is a one-chain toxin comprising 1,285 amino acids (aa) (7) . Different domains of PMT are involved in cell uptake and intracellular action. The receptor binding and translocation domains are located in the N terminus (aa 1 to 574). Whereas the receptor binding domain has not been characterized in detail, two amphipathic helices, covering residues 402 to 457, are suggested to be involved in membrane insertion and translocation (21) . So far, the cell surface receptor of PMT is not known (22) . The biologically active C-terminal part of PMT (aa 575 to 1285) was crystallized, and the structure revealed 3 domains (23) . Domain C1 (aa 575 to 719) has homology to the N-terminal portion of clostridial glycosyltransferases. It functions as an intracellular membrane localization domain (24, 25) . Whereas no function has been assigned to domain C2 (aa 720 to 1104), the C3 domain (aa 1105 to 1285) harbors the catalytic deamidase activity of PMT. This domain exhibits homology to papain-like cysteine proteases. The catalytic triad consists of Cys-1165, His-1205, and Asp-1220 (23, (26) (27) (28) .
Diphtheria toxin (DT) consists of three domains. The catalytically active domain (DTa) is localized at the N terminus, followed by the translocation (T) domain and the receptor binding (R) domain in the C terminus (29, 30) . During uptake, the active part (DTa) has to be cleaved by host proteases. Additionally, a disulfide bond between the proteolytically cleaved DTa and the translocation domain has to be reduced to release fully active DTa into the cytosol (31) . In the cytosol, DTa transfers an ADP-ribose moiety from NAD ϩ onto elongation factor 2 (EF-2) (32, 33). The accep-tor amino acid is diphthamide, a posttranslationally modified histidine residue. ADP-ribosylation of EF-2 by DTa inhibits protein synthesis and results in death of target cells (34) .
Here we present the construction of PMT-DTa fusion proteins on the basis of a non-cell-permeating DT fragment (DTa) and distinct fragments of PMT. The obtained fusion proteins reveal regions of PMT that transport a cargo protein into the cytosol of host cells. Additionally, fusion proteins were characterized in respect to specific steps of their uptake into host cells, e.g., receptor binding, intracellular trafficking, or pH-dependent translocation from endosomes into the cytosol.
MATERIALS AND METHODS
Materials. PCR primers were from Apara (Denzlingen, Germany). Diphtheria toxin was purchased from Calbiochem, and 32 P-NAD ϩ and [
14 C]leucine were purchased from PerkinElmer (Cologne, Germany). All other reagents were of analytical grade and were purchased from commercial sources.
Cloning and expression of PMT-DTa chimeras. The plasmid encoding the PMT-DTa chimera was generated by using the PMT C1165S -pGEX2T construct (26) . DTa (aa 26 to 216) was amplified with the following primer pair harboring BamHI restriction sites: DTa 26 sense (5=-ATAGGATCCGGC GCTGATGATGTTGTTGATTCTTC-3=) and DTa 216 anti (5=-ATAGGAT CCGACACGATTTCCTGCACAGGCTTGAG-3=). PMT C1165S -pGEX2T was digested at the 3= end with BamHI, and the DTa fragment was ligated into the open vector. The plasmids encoding PMT ⌬C -DTa, PMT 505 -DTa, and PMT 400 -DTa were generated by standard PCR techniques utilizing the PMT-DTa-pGEX2T construct and the primer DTa 26 sense (5=-GCAC TAGGATCCGGCGCTGATGATGTTGTTGAT-3=). The following corresponding primers were used: for PMT ⌬C -DTa (PMT aa 1 to 582), PMT 582 anti (5=-AGGACTATAAGGAGAGCCCCCTAATAGTTTAG-3=); for PMT 505 -DTa (PMT aa 1 to 505), PMT 505 anti (5=-AGGAGGATC ATCAGGTGAGATAGAATGTAA-3=); and for PMT 400 -DTa (PMT aa 1 to 400), PMT 400 anti (5=-TATTGCAGATAACTGTGAAATAAAGGTTT C-3=).
PMT, the catalytically inactive mutant PMT C1165S , and all PMT-DTa fusion proteins were expressed and purified as described previously (26) .
Cell culture. HEK-293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1% penicillin-streptomycin (P/S) in an atmosphere of 5% CO 2 at 37°C. The Caco-2 cell line was cultured in DMEM supplemented with 10% FCS, 1% P/S, 1% nonessential amino acids, and 1% sodium pyruvate. Cell lysates were prepared as follows. HEK-293 cells were washed twice with phosphate-buffered saline (PBS) (4°C), lysed in RIPA buffer (50 mM HEPES, 150 mM NaCl, 1% Triton X-100, 0.5% sodium desoxycholate, and 0.1% SDS) at 4°C, and centrifuged for 20 min at 14,000 rpm. Supernatants were used as cell lysates.
Trypsin activation. Diphtheria toxin (6.3 M) dissolved in PBS was incubated with 0.75 ng trypsin for 30 min at 25°C, and then 0.1 M dithiothreitol (DTT) was added for another 15 min (37°C). For activation of the PMT-DTa chimeras, equimolar amounts of fusion proteins were treated as mentioned above.
ADP-ribosylation of EF-2. Twenty-five micrograms of HEK-293 cell lysate was incubated for 30 min at 37°C with 4.6 kBq radioactive 32 P-NAD ϩ and toxin chimera at the indicated concentrations in 20 l ADPribosylation buffer (1 mM EDTA, 50 mM NaCl, 50 mM Tris-HCl [pH 7.5], 1 mM DTT, and 5 mM thymidine). Radiolabeled proteins were detected by SDS-PAGE and subsequent phosphorimaging (Molecular Dynamics). For post-ADP-ribosylation, HEK-293 cells were incubated with PMT-DTa (3 nM) for 6 h. After changing of the medium and further incubation overnight, cell lysates were acquired with RIPA buffer, and ADP-ribosylation was performed with 2.5 g lysate and 300 nM toxin as described above.
Cell viability assay. For determination of cytotoxicity, HEK-293 cells were cultured in complete medium in 96-well plates. Cells were incubated for 48 h with the indicated concentrations of DT and PMT-DTa chimeras at 37°C, and cell viability was determined by measuring the metabolic activity of cells, using the CellTiter-Blue assay (Promega, Mannheim, Germany). Fluorescent products were measured on a multiwell fluorescence reader (Infinite M200; Tecan, Crailsheim, Germany) according to the manufacturer's protocol.
Detection of protein biosynthesis. HEK-293 cells were incubated overnight with PMT-DTa or DT (3 nM) in 6-well plates. After changing from complete medium to medium without FCS, 1 Ci/ml [ 14 C]leucine was added and incubated for 1 h at 37°C. The cells were washed three times with PBS (4°C), and the proteins were precipitated with 10% trichloroacetic acid (TCA) (30 min, 4°C). The solution was centrifuged at 13,000 rpm for 20 min. The pellet was transferred to 500 l PBS and 2 ml Ultima Gold scintillation solution. The radioactivity of the incorporated [ 14 C]leucine was measured with a liquid scintillation counter (Tri-Carb 2900TR; Packard). Immunoblot analysis. Proteins were analyzed by immunoblotting after SDS-polyacrylamide gel electrophoresis. Anti-DTa antibody (GTX28308) was purchased from Acris Antibodies (Herford, Germany). Anti-PMT antibody was produced against a peptide in the N-terminal part of the toxin (aa 380 to 400). An enhanced chemiluminescence detection reagent (100 mM Tris-HCl [pH 8.0], 1 mM luminol (Fluka), 0.2 mM p-coumaric acid, and 3 mM H 2 O 2 ) was used to detect binding of a horseradish peroxidase-coupled secondary antibody with an LAS-3000 imaging system (Fujifilm).
Fluorescence labeling. PMT-DTa and PMT were N-terminally conjugated to fluorescein by using the sortase method (35, 36) and the fluorophore 5(6)-fluorescein-NH-Ahx-LPRT-COOMe (Thermo Scientific, Ulm, Germany).
Recombinant sortase A from Staphylococcus aureus (SrtA Staph ) with an N-terminal hexahistidine tag was expressed in Escherichia coli cells and purified according to the method of Ton-That et al. (37) . Sortase-mediated labeling of PMT was performed according to the method described by Antos et al. (36) , with slight alterations. PMT or PMT-DTa was incubated with 5(6)-fluorescein-NH-Ahx-LPRT-COOMe (500 M) and SrtA Staph (20 M) for 1 h at 37°C. SrtA Staph was removed by incubation with Protino Ni-IDA resin (Macherey-Nagel, Dueren, Germany). An excess of the fluorophore was removed by using a PD-10 column (GE Healthcare, Buckinghamshire, United Kingdom). Fluorophore-labeled PMT was separated by SDS-PAGE, and the fluorescence was detected by illuminating the SDS gel with a laser (488 nm) in a Typhoon 9200 scanner (GE Healthcare).
Fluorescence microscopy. Caco-2 cells were grown on HCl-washed glass coverslips to a confluence of 60 to 80%. Cells were intoxicated with labeled PMT or PMT-DTa (0.5 M) for different times: 30 min for early endosomal antigen 1 (EEA1) staining, 30 min for Rab5, 1 h for Rab7, 1 h for Rab11, 40 min for CTR433, and 1 h for LAMP1. Cells were washed with PBS and fixed with 4% paraformaldehyde in PBS for 15 min at room temperature. Thereafter, cells were washed with PBS and permeabilized with 0.15% Triton X-100 in PBS for 10 min. Cells were blocked for 1 h in a blocking solution (PBS with 1% bovine serum albumin and 0.05% 
RESULTS
A chimeric protein comprising the ADP-ribosyltransferase domain of DT (DTa) and PMT was constructed according to the scheme presented in Fig. 1 . To this end, the DNA of PMT encoding the full-length protein (aa 1 to 1285) was fused to the catalytically active domain of diphtheria toxin (DTa; aa 26 to 216). To avoid concomitant activity of PMT, a catalytically inactive point mutant of the C3 domain of PMT was utilized (C1165S mutant).
Proteins were expressed and purified as glutathione S-transferase (GST) fusion proteins and subsequently released from the GST tag by thrombin cleavage. PMT-DTa fusion proteins were analyzed by SDS-PAGE and immunoblotting (Fig. 1B) . Migration of fusion proteins in SDS-PAGE gels stained with Coomassie blue was in agreement with the calculated masses of the proteins. An antibody against the N terminus of PMT recognized PMT-DTa and wild-type PMT (PMT wt ) but not DT in the immunoblot analysis. Additionally, a DTa-directed antibody recognized PMT-DTa and DT but not PMT, confirming the complete expression of the chimera with the C-terminally fused DTa fragment.
The activity of the fused ADP-ribosyltransferase domain DTa was initially tested using an in vitro assay. PMT-DTa but not PMT wt induced ADP-ribosylation of EF-2 in a concentration-dependent manner ( Fig. 2A) . A time-dependent intoxication of HEK-293 cells by PMT-DTa was performed. Cell viability was measured by the CellTiter-Blue assay. After 22 h, a cytotoxic effect of PMT-DTa was detectable; the toxic effect increased during the incubation time of 48 h (Fig. 2B) . In contrast, native PMT wt affected cell viability only minimally after cell treatment and incubation for 48 h. The minor decrease in cell viability after 48 h may have been due to the mitogenic effect of PMT wt , which leads to faster medium wastage.
Modification of EF-2 in vivo by PMT-DTa was tested by a "post-ADP-ribosylation" assay. To this end, HEK-293 cells were intoxicated with PMT-DTa (3 nM) for the indicated times. Thereafter, cells were lysed, and an ADP-ribosylation assay with fresh toxin in the presence of 32 P-NAD ϩ was performed. As shown in Fig. 2C , increasing the time of cell incubation with PMT-DTa led to a reduction of [ 32 P]ADP-ribosylation of EF-2, indicating a modification of EF-2 with unlabeled ADP-ribose during cell intoxication.
The consequence of ADP-ribosylation of EF-2 by DTa is a blockade of protein synthesis (34) . Therefore, we determined protein synthesis by measuring the incorporation of (Fig. 2E) .
Characterization of cell uptake of PMT-DTa. The PMT-DTa chimera consists of the complete PMT toxin, encompassing all To further analyze the uptake of the PMT-DTa chimera, we tested whether the translocation of PMT-DTa from endocytic vesicles into the cytosol depended on a low pH of endosomes. HEK-293 cells were preincubated with bafilomycin A1, an inhibitor of vacuolar H ϩ -ATPases, to prevent acidification of endosomes. The cells were then treated with PMT-DTa, and ADP-ribosylation of EF-2 was determined, utilizing the post-ADP-ribosylation assay. As shown in Fig. 3B , bafilomycin A1 blocked PMT-DTa-induced ADP-ribosylation of EF-2 and rescued the [ 32 P]ADP-ribosylation signal. Thus, the uptake of PMT-DTa depends on a low pH of endosomes.
Furthermore, uptake into endocytic compartments and intracellular trafficking of PMT-DTa were studied by spinning disc microscopy with fluorescently labeled toxin. Therefore, PMTDTa and PMT were N-terminally transacylated by the enzyme sortase from Staphylococcus aureus (SrtA Staph ), using a synthetic peptide coupled to a fluorophore. Sortase-mediated transacylation depends on the recognition motif (LPRT) in the peptide and on glycine residues in the N terminus of the second protein, which were present in both constructs, PMT-DTa and PMT, due to the thrombin cleavage site. Hence, PMT-DTa and PMT were labeled with fluorescein at the N terminus and purified from sortase and residual fluorophore as shown in Fig. 4A . Colocalization studies were performed in Caco-2 cells because their morphology is advantageous for confocal microscopy. In contrast to HEK-293 cells, Caco-2 cells display a large portion of cytosol and increased cell height, favoring better representation of vesicles. Caco-2 cells were treated with fluorescein-labeled PMT-DTa or PMT for different times. Thereafter, cells were fixed and cellular compartments were visualized by specific marker proteins, using immunofluorescence. Rab5 and EEA1 were used as markers of early endosomes. Rab7 was used as a marker of late endosomes. Rab11 was used as a marker of recycling endosomes, LAMP-1 as a lysosomal marker, and CTR433 as a Golgi marker. As shown in Fig.  4B , PMT-DTa colocalized with EEA1, a marker of early endosomes. Colocalization with a marker of late endosomes (Rab7) was detectable with an intoxication time of 60 min. To prove that the intracellular trafficking of PMT was not hampered by the fusion to DTa, we additionally studied the trafficking of PMT. PMT also colocalized with markers of early endosomes (EEA1 and Rab5) and late endosomes (Rab7) (Fig. 4C) . Colocalization of PMT and PMT-DTa was calculated by an overlay approach (see Fig. S2 in the supplemental material) . Moreover, we did not detect any colocalization of PMT with markers of other compartments, such as recycling endosomes, lysosomes, or the Golgi apparatus.
Further chimeras of PMT-DTa were created to characterize the minimal region of PMT to serve as a transporter of the fused DTa domain. Three fusions of DTa and PMT were generated by standard PCR techniques. One construct lacks the C1 to C3 domains (PMT ⌬C -DTa), and one is missing the complete sequence downstream of the translocation domain of PMT (PMT 505 -DTa). PMT 400 -DTa consists only of the N-terminal part of PMT, without the putative translocation domain.
The activity of the fused ADP-ribosyltransferase domain (DTa) was tested using an in vitro assay. Cell lysates were incubated with chimeras or activated DT and 32 P-NAD ϩ -containing ADP-ribosylation buffer. All chimeras and activated DT (38, 39) exhibited catalytic activity as measured by ADP-ribosylation of EF-2. Whereas all tested chimeras were active, the extents of ADPribosylation varied (Fig. 5A) . The rank order of the degree of EF-2 modification by PMT-DTa chimeras was as follows: PMT 505 -DTa Ն PMT 400 -DTa ϭ PMT ⌬C -DTa Ͼ PMT-DTa. Moreover, we trypsin activated PMT-DTa fusions as was done for DT. Trypsin activation increased the activity of DT ϳ15-fold. However, the activity of PMT-DTa fusions was affected only 2-fold by trypsin treatment (Fig. 5B ).
Next, we tested the cell toxicity of DT and PMT-DTa chimeras. HEK-293 cells were intoxicated with fusion constructs (concentration range of 300 pM to 30 nM), and cell viability after 48 h was determined by the CellTiter-Blue assay (Fig. 5C ). Determination of cell toxicity revealed the strongest effect for full-length PMTDTa, followed by PMT 505 -DTa and PMT ⌬C -DTa, which showed nearly equal potencies. PMT 400 -DTa had no impact on cell viability at the tested concentrations. HEK-293 cells were treated with 0.3 nM PMT-DTa and increasing concentrations of PMT C1165S (as indicated). After 6 h, the medium was replaced with toxin-free medium and the incubation continued overnight. Cells were lysed, and post-ADP-ribosylation assays with 32 P-NAD ϩ were performed as described in Materials and Methods. (B) Influence of inhibition of endosome acidification by bafilomycin A1 on uptake of PMT-DTa. HEK-293 cells were treated without or with bafilomycin A1 (30 nM) for 30 min. Cells were intoxicated with PMT-DTa (3 nM) for 6 h, and the medium was replaced with fresh medium. After overnight incubation, cells were lysed, and post-ADP-ribosylation assays with 32 P-NAD ϩ were performed. Data shown are quantifications of ADP-ribosylation calculated by using Image Quant (GE Healthcare). The strongest signal produced by [ 32 P]ADP-ribosylation was defined as 100%. Data are representative results from at least three independent experiments. Quantified measurements are given as means Ϯ SE (n ϭ 3). Statistical significance was assessed by paired Student's t test. *, P Ͻ 0.05.
DISCUSSION
Bacterial protein toxins, i.e., exotoxins, are multifunctional proteins composed of various domains with distinct tasks. To target intracellular components of eukaryotic cells, at least two domains are necessary: one domain (B) to induce cellular uptake and one domain (A) which harbors the biological activity (40) . In most cases, the uptake domain can be subdivided into a receptor binding (R) domain and a translocation (T) domain. In a large array of toxins, the receptor binding domain induces binding and endocytosis into vesicular compartments, and the translocation domain allows the transport of the A domain from inside the vesicle into the cytosol. Studies from recent years have shown that it is possible to utilize the receptor binding/translocation domain of exotoxins to transport a cargo protein into eukaryotic cells (41) (42) (43) (44) (45) . Here we analyzed the transport of a non-cell-permeating toxin fragment (DTa) by using PMT as a transporter. We demonstrate that the DTa domain itself does not impair protein synthesis of cells (Fig. 2D) , although ADP-ribosylation activity remains in vitro (see Fig. S1 in the supplemental material). This indicates that DTa is insufficient to induce its own cellular uptake. Therefore, we constructed various chimeric proteins of PMT and the active domain of diphtheria toxin (DTa), starting with a full-length construct of PMT fused C-terminally to DTa (PMT-DTa). To avoid concurrent biological activities of the fusion of full-length PMT and DTa, a catalytically inactive point mutant of PMT (C1165S mutant) (26, 46) was used for PMT-DTa. Functionality of the PMT-fused DTa domain was confirmed by determination of the ADP-ribosyltransferase activity toward EF-2. PMT-DTa was able to modify EF-2 in an in vitro ADP-ribosylation assay, whereas PMT wt had no effect on EF-2. Time-dependent intoxication of HEK-293 cells was tested with PMT-DTa and showed a strong reduction of metabolic activity. In contrast, PMT wt did not impair cell viability. These data correlated with intracellular PMT-DTa-induced ADP-ribosylation, which was evident in a post-ADP-ribosylation assay. To further characterize the uptake of the PMT-DTa chimera, specific steps of cell intoxication were studied. Competition studies of PMT-DTa with PMT C1165S revealed binding of PMT-DTa and PMT to identical receptors. Translocation of PMT-DTa into the cytosol depends on acidification of the endosome, as revealed by inhibition of EF-2 ADP-ribosylation by PMT-DTa upon treatment with an inhibitor of vacuolar H ϩ -ATPase (47) . This is in congruence to previous findings that the biological effect of PMT depends on acidification during uptake (11, 21) . To follow intracellular trafficking, PMTDTa was labeled site specifically at the N terminus with a fluorescent epitope. To this end, a recently described method utilizing the enzyme sortase from Staphylococcus aureus was employed (35, 36) . The key advantage of the method is the small size of the label and the specificity of the labeled site. Hence, the possibility of impairing the trafficking route by the fluorescence label is reduced to a great extent. Colocalization studies identified labeled PMTDTa in early and late endosomes. It is known that the pH of endosomes is acidified during trafficking from early to late endosomes (48) . Therefore, the data suggest that PMT-DTa translocates from these compartments into the cytosol. In addition, similarly labeled PMT wt was found to colocalize with markers of early and late endosomes, indicating that the PMT-DTa chimera behaves like PMT wt . In contrast, PMT was not found in other compartments, such as recycling endosomes, lysosomes, or the Golgi apparatus. Thus, our results confirm previous findings that PMT traffics through early and late endosomes (49) .
To determine the minimal region of PMT sufficient for cellular uptake of DTa, truncations of PMT were constructed. The various chimeric fusion proteins exhibited different efficiencies in ADPribosylation of EF-2. While the short PMT-DTa chimeras (PMT ⌬C -DTa, PMT 505 -DTa, and PMT 400 -DTa) exhibited strong ADP-ribosylation activity toward EF-2, comparable to that of activated DT, the fusion protein PMT-DTa was surprisingly less active. Differences in the activity of the DTa domain might be due to structural restrictions of the fusion protein. Wild-type DT exhibits full ADP-ribosyltransferase activity only after proteolytic cleavage and reduction of the remaining disulfide bond, i.e., the biologically active DTa fragment has to be set free from the fulllength toxin (38, 39) . Accordingly, trypsin treatment of PMT-DTa fusions increased ADP-ribosylation activity. However, the increase of ADP-ribosylation activity of the PMT-DTa fusion was only 2-fold, compared to an ϳ15-fold increase detected with DT. These results indicate that in contrast to the case with DT, the ADP-ribosyltransferase activity was hardly inhibited by the overall structure of the fusion proteins. However, we cannot exclude that a specific proteolytic step is involved in the translocation and/or action of PMT. In this respect, it is interesting that CNF1, which exhibits sequence similarity with PMT over a large N-terminal region, is apparently proteolytically processed during its cellular uptake (50) . Whether this is also true for PMT remains to be analyzed. In the next step, we analyzed the ability of the PMT-DTa fusions to intoxicate eukaryotic cells by determination of the metabolic activity of HEK-293 cells. The fusion protein, comprising full-length PMT fused to DTa (PMT-DTa), was the most active construct. Whereas PMT 400 -DTa did not intoxicate cells, the other constructs (PMT 505 -DTa and PMT ⌬C -DTa) exhibited up to 10 times less activity than that of PMT-DTa. This is a surprising finding, because constructs that were highly active in ADP-ribosylation in vitro were found to be less potent in cell intoxication. 32 P-EF-2) was measured as described in Materials and Methods. The quantification of ADP-ribosylation was performed by using Image Quant (GE Healthcare), and data are shown as the fold induction over the level with DT. (B) DT and PMT-DTa chimeras were treated with trypsin as described in Materials and Methods. ADP-ribosylation of EF-2 was performed as described before. ADPribosylation of EF-2 by trypsin-treated toxin was calculated as the fold induction over the level with untreated toxin. Data shown are representative results from at least three independent experiments and are given as means and SE (n ϭ 3). (C) Cell viability is compromised in a concentration-dependent manner by PMT-DTa fusions. HEK-293 cells were intoxicated with DT or PMTDTa chimeras at the indicated concentrations (black circles, DT; open circles, PMT-DTa; black triangles, PMT 505 -DTa; open triangles, PMT ⌬C -DTa; and black squares, PMT 400 -DTa). Subsequently, cell viability was determined by the CellTiter-Blue assay. Data shown are cell viabilities normalized to the control and are given as means Ϯ SE (n ϭ 3).
This finding allows important conclusions to be drawn about the efficiency of the transport of fusion toxins and highlights the relevance of a coordinated function of the full-length multidomain toxin.
Our data indicate that a region of PMT as small as the N-terminal region covering residues 1 to 505 is suitable to induce uptake of a C-terminally fused protein such as DTa. This is in agreement with the proposed domain structure of PMT, including a receptor binding site in the far N terminus followed by a translocation domain (21) . This model is strengthened by the finding that a shortened PMT fragment (PMT 400 -DTa) without the full translocation domain was not able to transport the cargo into the cytosol. PMT ⌬C -DTa, which encompasses the N-terminal region of PMT from aa 1 to 582, exhibited the same potency in cell intoxication as PMT 505 -DTa. The full-length PMT protein is probably optimized in its translocation ability, suggesting that the additional C1 to C3 domains favor a toxin structure which is most rapidly translocated.
In conclusion, we present data showing that PMT can be utilized as a transporter to carry a non-cell-permeating protein (DTa) as a fusion protein into the cytosol of host cells. For this transport, the N terminus of PMT, encompassing residues 1 to 505, most likely covering the receptor binding and translocation domains, is sufficient. Our findings are of major importance for further analysis of the binding and translocation of PMT. For example, the PMT-DTa chimeras can be employed in gene trapping screens as a tool to identify the still unknown receptor of PMT. This screening is much easier with toxins which exhibit strong cytotoxic effects than with toxins which may cause morphological changes but do not kill cells rapidly, such as PMT.
